Completed PHASE3 INTERVENTIONAL NCT00362960

Olmesartan Medoxomil and Diabetic Nephropathy

Effect of Different Doses of Olmesartan Medoxomil Compared to Losartan on Proteinuria, Renal Function and Inflammatory Markers in Type 2 Diabetics With Nephropathy

Sponsor: Sankyo Pharma Gmbh

Conditions Diabetic Nephropathy Proteinuria Renal Disease Type 2 Diabetes Mellitus

Interventions Losartan Olmesartan medoxomil

Updated 8 times since 2017 Last updated: Oct 6, 2006 Started: May 31, 2003 Completion: Sep 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00362960, this PHASE3 trial focuses on Diabetic Nephropathy and Proteinuria and remains completed. Sponsored by Sankyo Pharma Gmbh, it has been updated 8 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Mar 2024 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Mar 2024 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Sep 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Sep 2017 [monthly]

Completed PHASE3

First recorded

May 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sankyo Pharma Gmbh

Data source: Daiichi Sankyo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Augsburg, Germany , Banská Bystrica, Slovakia , Barcelona, Spain , Frýdlant, Czechia , Greifenstein-Beilstein, Germany , Grodzisk Mazowiecki, Poland , Hanover, Germany , Košice, Slovakia , Krakow, Poland , Liberec, Czechia and 17 more locations